TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-20

Archived explainer. For the current picture see today's INSM page.

Why Is INSMED INC (INSM) Stock Up Today?

By the Top Tier Newswire AI Desk · November 20, 2026 at 12:02 AM ET · reviewed against 25 wire stories

INSMED INC (INSM) is up +20.58% in the latest session. Our newswire has captured 25 stories on INSM across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Insmed Inc (INSM) shares surged 20.58% to close at $144.46, driven by reports that Sanofi SA is considering an acquisition of the biopharmaceutical company. The move reflects growing speculation about a potential takeover, with analysts suggesting the deal could offer significant strategic value and a substantial premium to current market prices.

What Happened

Reports emerged that Sanofi SA is weighing a takeover of Insmed, a US drugmaker. This development sparked immediate interest in the stock, leading to a sharp intraday rally. BMO Capital analyst Conor MacKay noted that an acquisition makes considerable strategic sense for Sanofi. Meanwhile, RBC analysts rated the stock Outperform, estimating that a takeover could value shares between $170 and $210, implying a premium of 20% to 50%. Raymond James also highlighted the strategic value of Insmed amid the rumored bid.

The broader healthcare sector faced headwinds during the same session, with the NYSE Healthcare Index falling 2.1% and the State Street Health Care Select Sector SPDR ETF dropping 1.7%. Despite the sector-wide decline, Insmed bucked the trend due to the specific M&A speculation. The news was widely disseminated, with multiple financial outlets covering the potential deal and analyst reactions.

What The Data Shows

The stock’s 52-week range spans from $90.39 to $212.75, and the recent price action contributed to 12 fresh 52-week highs printed on November 19, 2026. Over the last eight sessions, the stock has moved up 20.9%, rising from $119.49 to its current level. Fundamentally, Insmed remains unprofitable with a trailing twelve-month EPS of -$2.80 and a net margin of -39.9%, though revenue has grown 240.0% year-over-year. The company has a market capitalization of $26.7 billion and a beta of 0.81.

Retail sentiment appears to be improving, with social chatter showing three posts in the last 24 hours and three in the last seven days. Recent insider filings show one sale totaling $3.1 million by director David R. Brennan in September 2026. Congressional disclosures indicate Donald J. Trump bought between $15,001 and $50,000 in July 2026 and sold between $1,001 and $15,000 in June 2026.

What To Watch

Investors will monitor further developments regarding the potential Sanofi acquisition and any official statements from either company. Additionally, the breadth of analyst coverage, which currently includes 25 stories from 11 sources in the last 36 hours, suggests continued high visibility and potential volatility as the deal speculation evolves.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

INSM by the numbers

Last: $144.46Session: +20.58%7 sessions: +20.90%Coverage: 25 stories / 11 sourcesAI sentiment: 64/100 (bullish)Mkt cap: $26.7B52w: $90.39 to $212.75
INSM · today's session (5-min) · +0.37% vs prior close · updated 12:44 PM ET
$142$146$149prev close $144.46$145.007:00 AM8:25 AM9:50 AM11:15 AM12:40 PM7:00 AM · $143.007:05 AM · $142.007:10 AM · $142.267:20 AM · $143.477:45 AM · $142.918:00 AM · $143.468:15 AM · $142.908:35 AM · $143.158:40 AM · $143.899:05 AM · $143.899:10 AM · $143.459:25 AM · $143.509:30 AM · $145.549:35 AM · $146.349:40 AM · $147.079:45 AM · $149.009:50 AM · $148.629:55 AM · $147.1610:00 AM · $146.3810:05 AM · $145.7810:10 AM · $145.2510:15 AM · $143.6310:20 AM · $143.7910:25 AM · $145.6010:30 AM · $146.4910:35 AM · $147.1010:40 AM · $146.3510:45 AM · $146.1210:50 AM · $145.6210:55 AM · $145.5411:00 AM · $145.7911:05 AM · $146.2211:10 AM · $146.7011:15 AM · $146.3411:20 AM · $145.9111:25 AM · $145.3111:30 AM · $144.8411:35 AM · $145.0911:40 AM · $145.4311:45 AM · $145.1611:50 AM · $145.3811:55 AM · $145.5312:00 PM · $145.1412:05 PM · $146.0912:10 PM · $146.3812:15 PM · $145.9412:20 PM · $146.0412:25 PM · $145.8112:30 PM · $145.3812:35 PM · $145.0012:40 PM · $145.00
AI sentiment, last 36h · averaged over 25 stories · 64/100 bullish
AI sentiment 64/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 62 · Insmed’s strategic value in focus amid rumored Sanofi bid, says Raymond JamesThe Fly · 62Insmed’s strategic value in focus amid rumored Sanofi bid, says Raymond JamesFidelity News · sentiment 42 · Sector Update: Healthcare Stocks Softer in Afternoon TradingFidelity News · 42Sector Update: Healthcare Stocks Softer in Afternoon TradingSeeking Alpha · sentiment 68 · Insmed may be worth $170 to $210 a share in takeover, analystSeeking Alpha · 68Insmed may be worth $170 to $210 a share in takeover, analystThe Fly · sentiment 64 · Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO CapitalThe Fly · 64Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO CapitalGuruFocus · sentiment 64 · Sanofi (SNY) Eyes Insmed Acquisition as Dividend Sustainability Remains a Core StrengthGuruFocus · 64Sanofi (SNY) Eyes Insmed Acquisition as Dividend Sustainability Remains a Core StrengthQuartz · sentiment 64 · Sanofi is weighing a takeover of U.S. drugmaker InsmedQuartz · 64Sanofi is weighing a takeover of U.S. drugmaker InsmedGuruFocus · sentiment 68 · Insmed (INSM) Surges 19% on Sanofi Acquisition Talks, Underscored by Mixed Valuation SignalsGuruFocus · 68Insmed (INSM) Surges 19% on Sanofi Acquisition Talks, Underscored by Mixed Valuation SignalsCNBC · sentiment 50 · Final Trade: DEO, ADP, AAPL, INSMCNBC · 50Final Trade: DEO, ADP, AAPL, INSM
19h agoCNBCNEUTRAL 50General

Final Trade: DEO, ADP, AAPL, INSM

The final trades of the day with CNBC’s Melissa Lee and the ‘Fast Money’ traders.

21h agoGuruFocusBULLISH 68M&A

Insmed (INSM) Surges 19% on Sanofi Acquisition Talks, Underscored by Mixed Valuation Signals

On November 19, 2026, shares of Insmed Inc (INSM) jumped 19% amid reports that Sanofi (SNY) is contemplating an acquisition of the biopharmaceutical company. Th

22h agoQuartzBULLISH 64M&A

Sanofi is weighing a takeover of U.S. drugmaker Insmed

22h agoGuruFocusBULLISH 64M&A

Sanofi (SNY) Eyes Insmed Acquisition as Dividend Sustainability Remains a Core Strength

On November 19, 2026, reports surfaced that Sanofi SA (NASDAQ: SNY) is considering an acquisition of Insmed, a move that BMO Capital analyst Conor MacKay views

22h agoThe FlyBULLISH 64M&A

Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO Capital

22h agoSeeking AlphaBULLISH 68M&A

Insmed may be worth $170 to $210 a share in takeover, analyst

RBC analyst rates Insmed Outperform: a Sanofi takeover could value shares at $170-$210, with a 20%-50% premium plausible.

23h agoFidelity NewsBEARISH 42M&A

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 2.1% and the State Street Health Care Select Sector SPDR ETF dropping 1.7%. The iShares Biotechnology ETF shed 0.1%. In corporate news, Sanofi (SNY.NaE) is mulling an acquisition of US drugmaker Insmed (INSM.NaE), Bloomberg reported.

23h agoThe FlyBULLISH 62M&A

Insmed’s strategic value in focus amid rumored Sanofi bid, says Raymond James

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on INSM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier INSM move explainers: 2026-11-20 · 2026-11-19 · 2026-10-30 · 2026-10-29 · 2026-10-06 · 2026-10-05 · 2026-08-07 · 2026-08-06